8-K: INVO Fertility, Inc. Faces Nasdaq Delisting Notice Due to Late Filing, Changes Name and Ticker Symbol

INVO Fertility, Inc., formerly NAYA Biosciences, received a Nasdaq notice for failing to file its annual report on time but plans to regain compliance, while also changing its name and ticker symbol.

Summary

• INVO Fertility, Inc. (formerly NAYA Biosciences, Inc.) received a notification from Nasdaq on April 16, 2025, because it did not file its Annual Report on Form 10-K for the year ended December 31, 2024, on time.
• This means the company doesn't meet Nasdaq Listing Rule 5250(c)(1).
• The notification doesn't immediately affect the listing of the company's stock, which continues to trade on the Nasdaq Capital Market under the symbol NAYA.
• INVO Fertility has 60 days from the date of the letter to submit a plan to regain compliance.
• If Nasdaq accepts the plan, the company could get an extension of up to 180 days from the filing's due date, until October 13, 2025, to comply.
• The company expects to file the report as soon as possible.
• On April 14, 2025, the company changed its name to INVO Fertility, Inc.
• The company intends for its common stock to cease trading under the ticker symbol NAYA and begin trading under its new ticker symbol, IVF, on the Nasdaq Capital Market, as promptly as possible.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the Nasdaq notification regarding the late filing of the annual report, which raises concerns about the company's compliance and financial reporting processes. However, the company is taking steps to address the issue, which provides some mitigation.

Positives

• The Nasdaq notification does not immediately affect the listing of the company's common stock.
• The company has the opportunity to submit a plan to regain compliance and potentially receive an extension.

Negatives

• The company failed to file its Annual Report on Form 10-K on time, resulting in a Nasdaq notification.
• The company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1).

Risks

• If the company fails to submit an acceptable plan to regain compliance, its common stock could be delisted from the Nasdaq Capital Market.
• The company's failure to file its annual report on time could negatively impact investor confidence.

Future Outlook

The company expects to file its Annual Report on Form 10-K as soon as practicable and intends to change its ticker symbol to IVF.

Industry Context

Delays in financial reporting can erode investor confidence, particularly in the competitive fertility industry where consistent performance and transparency are crucial for attracting investment and partnerships.

Stakeholder Impact

• Shareholders may be concerned about the potential delisting of the company's stock.
• Employees may experience uncertainty due to the company's non-compliance with Nasdaq listing rules.

Next Steps

• The company needs to submit a plan to Nasdaq to regain compliance with listing rules.
• The company needs to file its Annual Report on Form 10-K as soon as practicable.
• The company intends to change its ticker symbol from NAYA to IVF.

Key Dates

Keywords

INVO Fertility, NAYA Biosciences, Nasdaq, Delisting, Compliance, Annual Report, Ticker Symbol, IVF, Name Change